A meeting in Windhoek, Namibia, is bringing together private sector and government in an effort to develop legislation and practices governing biotrade and bioprospecting, according to an article in allAfrica.com. Namibia is currently drafting a bill on Access to Genetic Resources and Traditional Knowledge.
According to the report, the private sector is unwilling to stand up and announce a clear approach to ABS.
“They are averse to any negative publicity and believe that prior to any such event it is essential for them to have a clear position and approach to benefit sharing, and for many this is still work in progress,” said Jonathan Laundrey, New Business Manager of Phyto Trade Africa.
The focus on medicinal products, where “benefits” can indeed be very large, is not surprising as Namibia is the primary source of Devil’s Claw, Harpagophytum procumbens, a therapy for inflammation — notably arthritis — and other ailments. The value of exports is estimated at N$10 million a year. That’s “only” US $140,000, but in a country where more than a third of the people live on less than a dollar a day, a bigger share would probably help. An old press release from WHO suggests that organic, sustainable Devil’s Claw is the way forward, but enforcing that requires more than a bill on ABS.
Later … I’ve done a little more digging, and discovered a study published at the end of 2006 that has this to say on the value of Devil’s Claw:
In answer to the question of whether Devil’s Claw is fairly traded analysis of the value chain indicated that harvesters receive only 1.1% of the final consumer price of the active ingredient of Devil’s Claw. Of the final shelfÂvalue, only 7% is retained within the range states, a disappointingly low figure.